Your browser doesn't support javascript.
loading
Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.
Maltez, Nancy; Maxwell, Lara J; Rirash, Fadumo; Tanjong Ghogomu, Elizabeth; Harding, Sarah E; Tingey, Paul C; Wells, George A; Tugwell, Peter; Pope, Janet.
  • Maltez N; Department of Rheumatology, The Ottawa Hospital, Ottawa, Canada.
  • Maxwell LJ; Cochrane Musculoskeletal, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  • Rirash F; Department of Medicine, University of Western Ontario, London, Canada.
  • Tanjong Ghogomu E; Bruyère Research Institute, University of Ottawa, Ottawa, Canada.
  • Harding SE; Pediatric Critical Care Medicine, SUNY Upstate Medical University, Syracuse, USA.
  • Tingey PC; Department of Medicine, University of Western Ontario, London, Canada.
  • Wells GA; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
  • Tugwell P; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  • Pope J; Department of Medicine and Epidemiology and Biostatistics, University of Western Ontario, London, Canada.
Cochrane Database Syst Rev ; 11: CD014089, 2023 11 06.
Article en En | MEDLINE | ID: mdl-37929840
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerodermia Sistémica / Inhibidores de Fosfodiesterasa 5 Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerodermia Sistémica / Inhibidores de Fosfodiesterasa 5 Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article